Niraparib companion diagnostic - Myriad Genetics

Drug Profile

Niraparib companion diagnostic - Myriad Genetics

Alternative Names: BRACAnalysis (Niraparib); Niraparib - BRACAnalysis; Niraparib - BRACAnalysis CDx

Latest Information Update: 12 Apr 2017

Price : $50

At a glance

  • Originator Myriad Genetics
  • Developer Myriad Genetics; TESARO
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer; Ovarian cancer

Most Recent Events

  • 07 Oct 2016 Pharmacodynamics data from a clinical trial in Ovarian cancer released by Myriad Genetics
  • 24 Jun 2013 Myriad Genetics and TESARO enter into an agreement to use BRACAnalysis® as a companion diagnostic in phase III trials of niraparib in Ovarian and Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top